AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. AstraZeneca on Tuesday confirmed it has closed down its neuroscience research group to direct resources ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some breast cancer patients. Truqap was approved by the FDA in late 2023 to ...

AstraZeneca and health-tech company Qure.ai have completed the risk assessment of 5 million artificial intelligence (AI)-enabled chest X-rays (CXRs) across more than 20 countries in Asia, the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the ...

KALOS and LOGOS included approximately 4,400 randomized patients. Also Read: Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis The trials met all ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biopharmaceuticals Revenue Growth: 12% to $5.6 billion in Q1 2025. Rare Disease Revenue: $2 billion, stable year-on-year. AstraZeneca PLC (NASDAQ:AZN) reported a strong start to 2025 with a 10% ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the ...

The AstraZeneca PLC-Bond has a maturity date of 8/17/2048 and offers a coupon of 4.3750%. The payment of the coupon will take place 2,0 times per biannual on the 17.02.. At the current price of 85 ...